TD Asset Management Inc. reduced its position in Achaogen, Inc. (NASDAQ:AKAO) by 11.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 39,726 shares of the biopharmaceutical company’s stock after selling 5,100 shares during the period. TD Asset Management Inc. owned about 0.09% of Achaogen worth $634,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Marcus Capital LLC bought a new stake in Achaogen in the 2nd quarter worth approximately $1,769,000. Artal Group S.A. grew its position in Achaogen by 25.0% in the 3rd quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $3,988,000 after purchasing an additional 50,000 shares during the period. Bank of New York Mellon Corp grew its position in Achaogen by 68.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 191,670 shares of the biopharmaceutical company’s stock worth $4,165,000 after purchasing an additional 77,887 shares during the period. TimesSquare Capital Management LLC grew its position in Achaogen by 106.7% in the 2nd quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock worth $23,649,000 after purchasing an additional 561,700 shares during the period. Finally, Schwab Charles Investment Management Inc. bought a new stake in Achaogen in the 2nd quarter worth approximately $1,050,000. Institutional investors own 85.81% of the company’s stock.

Shares of Achaogen, Inc. (AKAO) opened at $11.12 on Friday. Achaogen, Inc. has a 1 year low of $10.24 and a 1 year high of $27.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99.

Achaogen (NASDAQ:AKAO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The firm had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $2.09 million. During the same quarter last year, the firm posted ($0.41) EPS. The firm’s quarterly revenue was down 96.4% compared to the same quarter last year. sell-side analysts forecast that Achaogen, Inc. will post -3.06 earnings per share for the current fiscal year.

In related news, COO Blake Wise sold 3,576 shares of Achaogen stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total transaction of $57,180.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.36% of the stock is currently owned by insiders.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Monday. Mizuho reissued a “buy” rating and set a $28.00 price objective on shares of Achaogen in a research report on Thursday, November 30th. Stifel Nicolaus cut their price objective on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, November 9th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Achaogen in a research report on Thursday, November 9th. Finally, Guggenheim assumed coverage on shares of Achaogen in a research report on Tuesday, October 24th. They set a “buy” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.78.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/15/achaogen-inc-akao-position-trimmed-by-td-asset-management-inc.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Want to see what other hedge funds are holding AKAO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achaogen, Inc. (NASDAQ:AKAO).

Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Stock Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related stocks with our FREE daily email newsletter.